Restarting Mounjaro after a 4-week break: the key decisions

Why four weeks changes the calculation

With Mounjaro, consistency matters. The medicine works by activating two gut-hormone receptors (GIP and GLP-1) to reduce appetite, slow gastric emptying, and help regulate blood sugar. Your system adapts to those effects over weeks, which is precisely why the licensed titration schedule starts at 2.5 mg and moves up slowly. When you stop, that adaptation starts to unwind.

A gap of roughly four weeks is not the same as missing a single injection. Missing two weeks is a shorter interruption, and many prescribers are comfortable with resumption at the same dose in that scenario. Four weeks is a different situation. The stomach-emptying effect that can cause nausea at higher doses tends to feel more pronounced after a prolonged break, because your gut has had time to return closer to its baseline. The NHS medicines guidance on tirzepatide acknowledges that side effects are most common when starting or increasing a dose; the same logic applies when restarting after a meaningful gap.

There is also a practical consideration. If your reason for stopping was side effects (nausea, fatigue, gastrointestinal discomfort) going straight back to the dose that caused them is unlikely to go well. Even if you stopped for an unrelated reason (illness, surgery, supply issues), your prescriber needs to know before you re-dose.

What your prescriber will actually weigh up

This is the decision at the centre of restarting tirzepatide after 4 weeks, and it belongs with a clinician rather than a guideline table. Your prescriber will typically consider four things: how long you were off it, the dose you were taking before the break, why you stopped, and whether anything has changed medically since then.

For breaks of around four weeks, many prescribers will recommend dropping back at least one dose step (for example, from 7.5 mg to 5 mg) and re-titrating from there. Some may suggest going back to 2.5 mg if the gap was accompanied by illness or significant weight change. The broader guidance on restarting Mounjaro covers the range of scenarios, but for a four-week break specifically, expect the conversation to be genuinely individual.

There is also the question of other medicines and your current health picture. Some over-the-counter medicines interact with tirzepatide in ways that are worth flagging at the same time as your restart review. If your circumstances have changed (new medicines, a new diagnosis, a change in weight) your prescriber needs that information before confirming anything.

Mounjaro is a prescription-only medicine. That means your prescriber, not a self-assessment, carries the clinical responsibility for your dose. A good prescriber will not simply re-issue the same pen automatically after a month's absence; they will ask questions. If yours does not, that is worth paying attention to.

Side effects to watch for when you restart

The most common effects after restarting are the same as when first starting: nausea, loose stools, indigestion, and occasionally fatigue. They tend to be most noticeable in the first few days after each injection. Restarting at a lower dose usually reduces their intensity, which is one reason prescribers recommend stepping down for a four-week gap.

The side effects you need to act on quickly are different. Severe stomach pain that spreads to the back, with or without vomiting, warrants urgent medical attention, the MHRA Drug Safety Update index covers the clinical background for healthcare professionals. More commonly, persistent vomiting or diarrhoea can lead to dehydration; if you cannot keep fluids down, contact a healthcare professional rather than waiting it out. The Yellow Card scheme at yellowcard.mhra.gov.uk is there if you want to report a side effect.

Women restarting Mounjaro while using oral contraceptives should be aware that tirzepatide can affect how the pill is absorbed. Adding a barrier method for the first four weeks of treatment (and for four weeks after any dose increase) is the recommended precaution per NHS guidance. If you were already familiar with this and had it in hand, it still applies when you restart as though beginning again.

Planning a smooth restart: practical steps

Before you inject, speak to your prescriber. That conversation is the single most useful step, and it does not need to be lengthy. If you are considering using a regulated online pharmacy, you can read more about Mounjaro as a treatment and tirzepatide more broadly to go into that conversation informed.

It is worth being honest about why you stopped. Prescribers hear this every week (supply problems, life getting in the way, side effects that felt manageable until they did not) and none of it is unusual. The clinical review is more useful the more complete the picture is.

If cost or supply was part of the reason for your break, the context around recent Mounjaro pricing changes in the UK may be relevant to your planning. Private treatment prices have moved since Eli Lilly adjusted their UK list price in September 2025, and understanding the landscape helps you make a sustainable choice. That is not a small thing, a treatment you can afford to stay on consistently works better than one you periodically stop.

People who restarted after a break of around a month sometimes find the first two or three weeks feel like starting over in terms of appetite changes and energy. That tends to settle. Restarting after a month and the slightly shorter window covered in restarting after three weeks are related guides if you want to compare the considerations across different gap lengths. For gaps longer than four weeks, a six-week break involves a slightly different clinical conversation again.

If you would like a prescriber to review your specific situation and confirm the right approach for you, checking your eligibility with our team is the right starting point. The consultation is free, and a named GPhC-registered prescriber will review your answers the same day.